Skip to main content
رجوع
PTGX logo

Protagonist Therapeutics, Inc.

جودة البيانات: 100%
PTGX
NASDAQ Healthcare Biotechnology
KWD 98.54
▼ KWD 0.33 (-0.33%)
القيمة السوقية: 6.29B
نطاق اليوم
KWD 98.15 KWD 102.06
نطاق 52 أسبوعًا
KWD 39.60 KWD 105.69
حجم التداول
905,200
متوسط 50 يوم / 200 يوم
KWD 87.11 / KWD 72.76
الإغلاق السابق
KWD 98.87

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -48.3 0.4
P/B 10.2 2.9
ROE % -20.2 3.8
Net Margin % -282.8 3.9
Rev Growth 5Y % 13.9 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 113.600 +15.3%
Low: KWD 108.000 High: KWD 121.000
مكرر الربحية المستقبلي
30.5
ربحية السهم المستقبلية
KWD 3.229
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
440 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 4.645
-KWD 0.614 – KWD 9.063
600 M 2
FY2029 KWD 2.568
-KWD 0.340 – KWD 5.011
420 M 4
FY2028 KWD 1.556
-KWD 7.558 – KWD 10.537
300 M 6

النقاط الرئيسية

Revenue grew 13.88% annually over 5 years — strong growth
Earnings declined -147.29% over the past year
Debt/Equity of 0.02 — conservative balance sheet
Generating 56.08M in free cash flow
PEG of 0.29 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 103.29%

النمو

Revenue Growth (5Y)
13.88%
Revenue (1Y)-89.41%
Earnings (1Y)-147.29%
FCF Growth (3Y)N/A

الجودة

Return on Equity
-20.18%
ROIC-18.97%
Net Margin-282.83%
Op. Margin-343.63%

الأمان

Debt / Equity
0.02
Current Ratio12.71
Interest Coverage0.00

التقييم

P/E Ratio
-48.31
P/B Ratio10.23
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -89.41% Revenue Growth (3Y) -12.43%
Earnings Growth (1Y) -147.29% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 13.88% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 46.02M Net Income (TTM) -130.15M
ROE -20.18% ROA -19.43%
Gross Margin 97.34% Operating Margin -343.63%
Net Margin -282.83% Free Cash Flow (TTM) 56.08M
ROIC -18.97% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.02 Current Ratio 12.71
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -48.31 P/B Ratio 10.23
P/S Ratio 136.64 PEG Ratio 0.29
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 6.29B Enterprise Value 6.17B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 46.02M 434.43M 60.00M 26.58M 27.36M
Net Income -130.15M 275.19M -78.96M -127.39M -125.55M
EPS (Diluted) -2.05 4.23 -1.39 -2.52 -2.65
Gross Profit 44.79M 434.43M 60.00M 26.58M 27.36M
Operating Income -158.13M 252.84M -93.65M -131.37M -125.85M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 669.89M 744.73M 357.95M 247.93M 347.70M
Total Liabilities 55.19M 69.43M 21.27M 32.32M 47.67M
Shareholders' Equity 614.71M 675.30M 336.68M 215.61M 300.02M
Total Debt 10.32M 10.87M 1.14M 3.66M 5.86M
Cash & Equivalents 128.39M 97.25M 186.73M 125.74M 123.67M
Current Assets 577.57M 591.64M 355.58M 243.08M 340.74M
Current Liabilities 45.44M 47.40M 21.27M 31.18M 44.02M